NCT07373613Not yet recruitingPhase 2
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- First submitted
- 20 Jan 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Diseases
- High blood pressure
- NCT number
- NCT07373613
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 330
- From 1 Mar 2026 to the primary completion date, 1 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
Other
- Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2)
- Patients with shock
- Patients with orthostatic hypotension accompanied by symptoms
Who the study is looking for
- \<Screening Visit (V1)\>
- Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:
- For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP \< 180 mmHg
- For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP \< 180 mmHg
- For patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study.
- \<Baseline Visit (V2)\>
- Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:
- For patients without cardiovascular disease: 140 mmHg ≤ MSSBP \< 180 mmHg
- For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP \< 180 mmHg
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hanyang University Hospital Coordinator of this site? Confirm its status | Soeul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.